| ELICIO THERAPEUTICS |
| USA |
| Gesundheit |
| US28657F1030 / A3CY4J |
| 9HA (Frankfurt) / ELTX (NASDAQ) |
| FRA:9HA, ETR:9HA, 9HA:GR, NASDAQ:ELTX |
| - |
| https://elicio.com/ |
|
Elicio Therapeutics Inc. is a clinical-stage biotechnology company focused on developing lymph node-targeted immunotherapies for cancer. The company’s current pipeline centers on its Amphiphile (AMP) platform, which is designed to deliver vaccines,..
>Volltext.. |
| 46.84 Mio. EUR |
| 38.52 Mio. EUR |
| - |
| -32.78 Mio. EUR |
| -33.72 Mio. EUR |
| -1.88 EUR |
| 12.61 Mio. EUR |
| 20.93 Mio. EUR |
| -33.59 Mio. EUR |
| 2.55 |
| - |
| 30.71% |
| - |
| - |
| - |
| - |
| ELICIO |
| 23.10.26 |
|